Cargando…

Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to Progression

Circulating tumor cells (CTCs) are promising biomarkers for prognosis, therapeutic response prediction, and treatment monitoring in cancer patients. Despite its epithelial origin, renal cell carcinoma (RCC) shows low expression of epithelial markers hindering CTC-enrichment approaches exploiting epi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cappelletti, Vera, Verzoni, Elena, Ratta, Raffaele, Vismara, Marta, Silvestri, Marco, Montone, Rosanna, Miodini, Patrizia, Reduzzi, Carolina, Claps, Melanie, Sepe, Pierangela, Daidone, Maria Grazia, Procopio, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073151/ https://www.ncbi.nlm.nih.gov/pubmed/32098246 http://dx.doi.org/10.3390/ijms21041475

Ejemplares similares

Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience
por: Sepe, Pierangela, et al.
Publicado: (2019)

The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice
por: Raimondi, Alessandra, et al.
Publicado: (2019)

Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma
por: Sepe, Pierangela, et al.
Publicado: (2021)

Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?
por: Mennitto, Alessia, et al.
Publicado: (2020)

A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer
por: Reduzzi, Carolina, et al.
Publicado: (2019)

BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients
por: Buti, Sebastiano, et al.
Publicado: (2022)

Metabolic Footprints and Molecular Subtypes in Breast Cancer
por: Cappelletti, Vera, et al.
Publicado: (2017)

Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy
por: Bottiglieri, Achille, et al.
Publicado: (2022)

Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
por: Raimondi, Alessandra, et al.
Publicado: (2020)

Detection of Genomically Aberrant Cells within Circulating Tumor Microemboli (CTMs) Isolated from Early-Stage Breast Cancer Patients
por: Silvestri, Marco, et al.
Publicado: (2021)

Detection of Circulating Tumour Cells in Urothelial Cancers and Clinical Correlations: Comparison of Two Methods
por: Fina, Emanuela, et al.
Publicado: (2017)

Stromal Activation by Tumor Cells: An in Vitro Study in Breast Cancer
por: Merlino, Giuseppe, et al.
Publicado: (2016)

Prognostic and functional role of subtype‐specific tumor–stroma interaction in breast cancer
por: Merlino, Giuseppe, et al.
Publicado: (2017)

Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer
por: Reduzzi, Carolina, et al.
Publicado: (2021)

Dissecting Time- from Tumor-Related Gene Expression Variability in Bilateral Breast Cancer
por: Callari, Maurizio, et al.
Publicado: (2018)

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
por: Grassi, Paolo, et al.
Publicado: (2016)

The Detection and Morphological Analysis of Circulating Tumor and Host Cells in Breast Cancer Xenograft Models
por: Cleris, Loredana, et al.
Publicado: (2019)

Predicting Molecular Models: Where Are We Going?
por: Ratta, Raffaele, et al.
Publicado: (2015)

Clinical Significance of Early Changes in Circulating Tumor Cells from Patients Receiving First-Line Cisplatin-Based Chemotherapy for Metastatic Urothelial Carcinoma(1)
por: Fina, Emanuela, et al.
Publicado: (2016)

Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma
por: Sepe, Pierangela, et al.
Publicado: (2020)

1647TiP Antiandrogen therapy and TMPRSS2 status: How prostate cancer patients are protected from COVID-19 pandemic
por: Claps, M., et al.
Publicado: (2021)

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
por: Grassi, Paolo, et al.
Publicado: (2017)

Use of Formalin-Fixed Paraffin-Embedded Samples for Gene Expression Studies in Breast Cancer Patients
por: Musella, Valeria, et al.
Publicado: (2015)

Gene signatures of circulating breast cancer cell models are a source of novel molecular determinants of metastasis and improve circulating tumor cell detection in patients
por: Fina, Emanuela, et al.
Publicado: (2022)

Integrative Transcriptomic Analysis Reveals Distinctive Molecular Traits and Novel Subtypes of Collecting Duct Carcinoma
por: Gargiuli, Chiara, et al.
Publicado: (2021)

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
por: Procopio, Giuseppe, et al.
Publicado: (2022)

Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer
por: Silvestri, Marco, et al.
Publicado: (2022)

Concomitant medications and circulating tumor cells: friends or foes?
por: Di Cosimo, Serena, et al.
Publicado: (2023)

Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice
por: Grassi, Paolo, et al.
Publicado: (2016)

In-depth characterization of breast cancer tumor-promoting cell transcriptome by RNA sequencing and microarrays
por: Callari, Maurizio, et al.
Publicado: (2015)

miR-30e* is an independent subtype-specific prognostic marker in breast cancer
por: D'Aiuto, F, et al.
Publicado: (2015)

Integrated transcriptional‐phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients
por: Rinchai, Darawan, et al.
Publicado: (2021)

Better together: circulating tumor cell clustering in metastatic cancer
por: Schuster, Emma, et al.
Publicado: (2021)

Contribution of vascular endothelial growth factor to the Nottingham prognostic index in node-negative breast cancer
por: Coradini, D, et al.
Publicado: (2001)

Early stage breast cancer follow-up in real-world clinical practice: the added value of cell free circulating tumor DNA
por: La Rocca, E., et al.
Publicado: (2022)

Accurate Data Processing Improves the Reliability of Affymetrix Gene Expression Profiles from FFPE Samples
por: Callari, Maurizio, et al.
Publicado: (2014)

The two phyto-oestrogens genistein and quercetin exert different effects on oestrogen receptor function
por: Miodini, P, et al.
Publicado: (1999)

Challenges in Using Circulating miRNAs as Cancer Biomarkers
por: Tiberio, Paola, et al.
Publicado: (2015)

Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors
por: Roviello, Giandomenico, et al.
Publicado: (2022)

PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls
por: Franza, A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dfcuq5lsphhbrarv67lc9n3t36